I've now recently started tripping 4-6 times a week. I think I have some tolerance issues.
I also use ketamine all the time with psychedelics and very often GHB also.
Read more about psychedelic-addiction:
Today I have taken 3,5mg of DOC IM and 2mg p.o. Maybe 1g of Ketamine IM (usually 60-120mg at once). 40-60mg of 2C-E. Some Methylone. Some Meth. Some Cocaine. Some GHB.
It's quite expensive to use that much drugs everyday, but I think that especially psychedelics and ketamine have changed my personality in a very wonderful way. I used to be very depressed, but now life seems like a wonder ride.
I'd recommed anyone to try this combination in a good set & setting: 15mg 2C-E p.o, wait 1h, take 3g of NaGHB, wait 30min, take 120mg of Ketamine IM.
And now to my question:
Does anyone know anything else than these that could prevent tolerance to psychedelics (because I don't really now where to get naloxone ?
Influence of naloxone on the effects of LSD in monkeys.
Hadorn DC, Anistranski JA, Connor JD.
Neuropharmacology. 1984 Nov;23(11):1297-300.
Three stump-tailed monkeys were trained in an appetitive behavioral task. Administration of 0.1 mg/kg of lysergic acid diethylamide (LSD) moderately disrupted performance acutely, and produced abnormal motor activity. With repeated administration of LSD, motor activity and task responding returned to normal. When 1.0 mg/kg of naloxone was administered prior to administration of LSD in a crossover design, appetitive responding was abolished acutely in all animals and behavior was substantially more disrupted than with LSD alone. Tolerance did not occur with repeated administration of this combination of drugs. Endorphins and/or opiate receptors may act to attenuate the effects of hallucinogenic agents, and may subserve the development of tolerance to these effects.
Pharmacol Biochem Behav. 1986 Feb;24(2):401-5.
Before the advent of neuroleptics, opioids such as morphine were used occasionally in the treatment of schizophrenia and other mental disorders. Recent interest in the possible therapeutic role of endogenous opioid peptides in various mental states has prompted a new look at the opioids. The present paper summarizes the research to date in the author's laboratory on opioid-hallucinogen interactions. A model behavioral state was induced in rats with N,N-dimethyltryptamine (DMT) or lysergic acid diethylamide-25 (LSD). Several mu opioid agonists, antagonists, and synthetic enkephalin analogs interacted with DMT and LSD. Adult male Holtzman rats trained on a positive reinforcement fixed ratio four (FR4) behavioral schedule (i.e., a reward of 0.01 ml sugar-sweetened milk was earned on every fourth bar press) were used in these studies. DMT (3.2 and 10.0 mg/kg) given with a 0.9% NaCl pretreatment IP, disrupted established food rewarded FR4 bar pressing behavior in a dose related fashion. Pre-determined behaviorally ineffective doses of mu opioid agonists showed selective biphasic effects against DMT and LSD. Low doses antagonized the effects of both hallucinogens, whereas larger doses enhanced their effects. In contrast to the antagonistic effects of low doses of mu opioid agonists, the mu-kappa opioid antagonist (-)-naloxone enhanced the effects of DMT and LS. (-)-Naloxone enhanced the effects of DMT and LSD. Potentiation of DMT-induced behavioral disruption was attributed to a stereospecific opioid antagonist effect of (-)-naloxone in that the (+)-naloxone enantiomer failed to potentiate the effects of DMT. Further studies are indicated to determine hallucinogen-opioid interactions in various species, including man.(ABSTRACT TRUNCATED AT 250 WORDS)